Biohaven signs Ono Pharma licensing for BHV-1300 in Asia
Biohaven said it entered a strategic licensing agreement with Ono Pharma covering extracellular IgG degraders in Japan and select Asian regions, with lead candidate BHV-1300 in Phase 3 for Graves' disease.